首页> 美国卫生研究院文献>Oncoimmunology >Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity

【2h】

Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity

机译：抗CD137增强了系统性B细胞淋巴瘤的抗CD20治疗免疫稳态改变但毒性可忽略不计

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Oncoimmunology
作者
Fernando Souza-Fonseca-Guimaraes; Stephen J. Blake; Amani Makkouk; Cariad Chester; Holbrook E. Kohrt; Mark J. Smyth;
展开▼
作者单位

展开▼
年(卷),期 2016(5),7
年度 2016
页码 e1192740
总页数 14
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity [J] . Souza-Fonseca-Guimaraes Fernando, Blake Stephen J., Makkouk Amani, Oncoimmunology. . 2016,第7期

机译：抗CD137增强了系统性B细胞淋巴瘤的抗CD20治疗，具有改变的免疫稳态，但毒性可忽略不计
2. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias [J] . GuptaP., GoldenbergD.M., RossiE.A., Blood: The Journal of the American Society of Hematology . 2010,第17期

机译：六价，单特异性，抗CD20和六价，双特异性，抗CD20 / CD22人源化抗体诱导的多种信号通路与对B细胞淋巴瘤和白血病的增强毒性相关
3. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. [J] . Mossner E, Brunker P, Moser S, Blood: The Journal of the American Society of Hematology . 2010,第22期

机译：通过改造具有增强的直接和免疫效应细胞介导的B细胞细胞毒性的新型II型抗CD20抗体，提高CD20抗体疗法的功效。
4. Prolonged Remission and Survival in Canine B-Cell Lymphoma After Chemotherapy and Low-Dose Rate Half-Body Radiotherapy [C] . American College of Veterinary Internal Medicine Forum Conference . 2019

机译：化疗后犬B细胞淋巴瘤的延长缓解和存活和低剂量率半体放射治疗
5. Effectiveness of Novel Immunotherapy and Chemotherapy Treatments for Follicular and Diffuse Large B-Cell Lymphomas [D] . Butsenko, Dmitriy. 2017

机译：新型免疫疗法和化学疗法对滤泡性和弥漫性大B细胞淋巴瘤的疗效
6. Immunobiology: Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity [O] . Ekkehard Mössner, Peter Brünker, Samuel Moser, -1

机译：免疫生物学：通过设计具有增强的直接和免疫效应细胞介导的B细胞细胞毒性的新型II型抗CD20抗体提高CD20抗体疗法的功效
7. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity [O] . Moessner, Ekkehard, Bruenker, Peter, Moser, Samuel, 2010

机译：通过改造具有增强的直接和免疫效应细胞介导的B细胞细胞毒性的新型II型抗CD20抗体，提高CD20抗体疗法的功效

Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity

著录项

引文网络

相似文献

相关主题

期刊订阅